| Not Yet Recruiting | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (N Multiple Myeloma (MM) | Phase 2 / Phase 3 | 2026-06-05 |
| Not Yet Recruiting | A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in He Healthy Volunteer | Phase 1 | 2026-05-07 |
| Not Yet Recruiting | First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Derm Healthy Volunteer, Atopic Dermatitis | Phase 1 | 2026-05-04 |
| Not Yet Recruiting | A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Phase 2 | 2026-04-20 |
| Not Yet Recruiting | A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hyperchol Hypercholesterolemia | Phase 2 | 2026-04-14 |
| Not Yet Recruiting | Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hemato Venous Thromboembolism (VTE) | Phase 3 | 2026-04-07 |
| Recruiting | A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurre Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | 2026-03-31 |
| Recruiting | A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Noc Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | 2026-03-31 |
| Not Yet Recruiting | Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Dise Peripheral Artery Disease (PAD) | Phase 3 | 2026-03-31 |
| Recruiting | A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relap Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | 2026-03-26 |
| Not Yet Recruiting | A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) High Risk Smoldering Multiple Myeloma (HR-SMM) | Phase 3 | 2026-03-25 |
| Recruiting | A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Call CHAPLE Disease | Phase 4 | 2026-03-19 |
| Not Yet Recruiting | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagu Atrial Fibrillation (AF) | Phase 3 | 2026-03-18 |
| Recruiting | A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non Advanced/Metastatic Non-Small Cell Lung Cancer | Phase 2 | 2026-03-18 |
| Recruiting | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US Overweight or Obesity | Phase 2 | 2026-03-16 |
| Recruiting | Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy Generalized Lipodystrophy | Phase 3 | 2026-03-13 |
| Recruiting | A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea Functional Hypothalamic Amenorrhea (FHA) | Phase 2 | 2026-03-11 |
| Recruiting | REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis Cancer-Associated Thrombosis (CAT) | Phase 3 | 2026-03-09 |
| Recruiting | A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Fa Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia | Phase 1 / Phase 2 | 2026-02-11 |
| Recruiting | A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescent Monogenic Obesity | Phase 3 | 2026-02-09 |
| Not Yet Recruiting | Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) Pulmonary Arterial Hypertension (PAH) | Phase 2 | 2026-01-29 |
| Recruiting | Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants Geographic Atrophy (GA) | Phase 1 | 2026-01-19 |
| Recruiting | Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy Allergic Conjunctivitis | Phase 3 | 2026-01-10 |
| Recruiting | Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Dia Diabetic Kidney Disease (DKD) | Phase 2 | 2026-01-09 |
| Recruiting | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 3 | 2026-01-02 |
| Recruiting | Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis Lupus Nephritis (LN) | Phase 1 | 2025-12-22 |
| Recruiting | A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants Active Noninfectious Uveitis Affecting the Posterior Segment | Phase 1 / Phase 2 | 2025-12-17 |
| Recruiting | First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD) Parkinsons Disease | Phase 1 | 2025-12-05 |
| Recruiting | REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adul Symptomatic Venous Thromboembolism (VTE) | Phase 3 | 2025-11-24 |
| Withdrawn | Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab Severe Atopic Dermatitis (AD) | Phase 4 | 2025-11-11 |
| Recruiting | A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells Long Term Safety Following GM T Cell Therapy | — | 2025-11-10 |
| Recruiting | A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic E Eosinophilic Esophagitis (EoE) | Phase 3 | 2025-11-10 |
| Recruiting | Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation Atrial Fibrillation (AF) | Phase 2 | 2025-10-20 |
| Completed | Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study Retinal Vasculitis | — | 2025-07-15 |
| Completed | A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibe Retinal Vasculitis | — | 2025-07-01 |
| Withdrawn | A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF), Biallelic Mutations in the Gap Junction Beta 2 (GJB2) Gene, Digenic Mutations in GJB2/Gap Junction Beta 6 (GJB6) Genes | — | 2025-06-30 |
| Recruiting | REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults Venous Thromboembolism (VTE) | Phase 3 | 2025-06-25 |
| Withdrawn | Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women Obesity | Phase 1 | 2025-05-29 |
| Recruiting | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | Phase 2 | 2025-05-28 |
| Active Not Recruiting | A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension Sepsis-Induced Hypotension | Phase 2 | 2025-05-05 |
| Recruiting | A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Dise Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis | Phase 1 | 2025-04-28 |
| Terminated | REGN5381 in Adult Participants With Uncontrolled Hypertension Uncontrolled Hypertension | Phase 2 | 2025-04-16 |
| Enrolling By Invitation | A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Trea Melanoma | Phase 2 | 2025-04-14 |
| Active Not Recruiting | Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults Healthy Volunteer | Phase 1 | 2025-03-06 |
| Completed | Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults Healthy Volunteer | Phase 1 | 2025-03-04 |
| Completed | ALN-APOC3 in Adult Participants With Dyslipidemia Dyslipidemia | Phase 1 | 2025-01-27 |
| Recruiting | Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 3 | 2025-01-02 |
| Active Not Recruiting | A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavad Generalized Lipodystrophy | Phase 3 | 2024-12-16 |
| Withdrawn | An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME) | — | 2024-12-12 |
| Recruiting | A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Pa Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | 2024-12-11 |
| Recruiting | A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Eosinophilic Esophagitis (EoE) | — | 2024-11-22 |
| Completed | A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Part Allergic Conjunctivitis | Phase 3 | 2024-11-19 |
| Recruiting | A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for A Non-Small Cell Lung Cancer | Phase 2 | 2024-11-18 |
| Withdrawn | Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participa Cutaneous Squamous Cell Carcinoma | Phase 2 | 2024-11-14 |
| Recruiting | Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycar Postural Orthostatic Tachycardia Syndrome (POTS) | Phase 2 | 2024-11-13 |
| Completed | A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Par Allergic Conjunctivitis | Phase 3 | 2024-11-06 |
| Recruiting | A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone Age-related Macular Degeneration (AMD), Geographic Atrophy (GA) | Phase 3 | 2024-10-30 |
| Completed | Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus Healthy Volunteers | Phase 1 | 2024-09-30 |
| Recruiting | A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for t Non-Transfusion Dependent Beta-Thalassemia (NTDT) | Phase 2 | 2024-09-30 |
| Recruiting | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemipl Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors | Phase 1 / Phase 2 | 2024-09-23 |
| Completed | A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adu Venous Thromboembolism | Phase 2 | 2024-09-20 |
| Active Not Recruiting | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participant Melanoma | Phase 2 | 2024-09-18 |
| Recruiting | A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to M Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) | Phase 2 | 2024-09-16 |
| Recruiting | A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131 Hemophilia B | Phase 1 / Phase 2 | 2024-09-11 |
| Recruiting | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metast Melanoma | Phase 3 | 2024-09-09 |
| Recruiting | First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene | Phase 1 / Phase 2 | 2024-08-28 |
| Recruiting | Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Compa Asthma | Phase 4 | 2024-08-26 |
| Recruiting | A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Relapsed/Refractory Systemic Light Chain Amyloidosis | Phase 1 / Phase 2 | 2024-08-07 |
| Recruiting | A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer | Phase 1 | 2024-08-06 |
| Active Not Recruiting | A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Ag Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema | Phase 3 | 2024-07-24 |
| Active Not Recruiting | A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than t Resectable Non-small Cell Lung Cancer | Phase 2 | 2024-07-16 |
| Completed | A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Particip Venous Thromboembolism | Phase 2 | 2024-06-27 |
| Active Not Recruiting | A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Ad Healthy Volunteers With Hyperlipidemia | Phase 1 | 2024-06-27 |
| Completed | A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH), Genetic Risk Factor | Phase 1 | 2024-05-21 |
| Recruiting | Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin Food Allergy | Phase 1 | 2024-05-17 |
| Completed | Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD) | Phase 3 | 2024-04-15 |
| Terminated | REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction Heart Failure | Phase 2 | 2024-04-11 |
| Active Not Recruiting | A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well Obesity | Phase 2 | 2024-03-13 |
| Active Not Recruiting | Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Adv Advanced Non-small Cell Lung Cancer | — | 2024-02-21 |
| Recruiting | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants Wi B-Cell Non-Hodgkin Lymphoma (B-NHL) | Phase 3 | 2024-02-15 |
| Active Not Recruiting | A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smolderi Smoldering Multiple Myeloma (SMM) | Phase 2 | 2024-01-30 |
| Active Not Recruiting | A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis W Hemophilia B | — | 2024-01-17 |
| Recruiting | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combine Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) | Phase 3 | 2023-12-28 |
| Recruiting | A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in A Multiple Myeloma | Phase 1 / Phase 2 | 2023-12-19 |
| Active Not Recruiting | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Diffuse Large B-cell Lymphoma (DLBCL) | Phase 3 | 2023-12-13 |
| Recruiting | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combin Follicular Lymphoma (FL) | Phase 3 | 2023-12-12 |
| Completed | A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Healthy Volunteers | Phase 1 | 2023-12-06 |
| Completed | A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults Healthy Volunteers | Phase 1 | 2023-11-28 |
| Active Not Recruiting | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works C Follicular Lymphoma (FL) | Phase 3 | 2023-11-14 |
| Recruiting | An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transp Chronic Kidney Disease (CKD) | — | 2023-10-19 |
| Recruiting | A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexa Relapsed Refractory Multiple Myeloma (RRMM) | Phase 3 | 2023-09-18 |
| Active Not Recruiting | A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemipli Non-small Cell Lung Cancer | Phase 2 / Phase 3 | 2023-08-08 |
| Completed | A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants Healthy Volunteers | Phase 1 | 2023-08-07 |
| Active Not Recruiting | A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Ad Advanced Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | 2023-06-30 |
| Completed | A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossifi Fibrodysplasia Ossificans Progressiva (FOP) | — | 2023-06-29 |
| Recruiting | A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss D Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | Phase 1 / Phase 2 | 2023-06-27 |
| Completed | A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Pa Venous Thromboembolism | Phase 2 | 2023-05-24 |
| Active Not Recruiting | A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis Wit Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID) | Phase 2 | 2023-05-03 |
| Active Not Recruiting | A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combinati Advanced Non-Small Cell Lung Cancer | Phase 2 | 2023-04-21 |
| Recruiting | A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B B-cell Non-Hodgkins Lymphoma (B-NHL) | Phase 1 | 2023-04-12 |
| Recruiting | A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatm Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | 2023-03-07 |
| Recruiting | A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfuncti Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | 2023-02-09 |
| Recruiting | A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cem Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | 2023-02-07 |
| Active Not Recruiting | A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing Melanoma | Phase 3 | 2023-01-16 |
| Completed | A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How i Healthy Volunteer | Phase 1 | 2023-01-12 |
| Completed | Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial Moderate-to-Severe Atopic Dermatitis, Atopic Eczema | Phase 4 | 2023-01-11 |
| Completed | Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Relapsed and Refractory Multiple Myeloma (RRMM) | — | 2023-01-09 |
| Completed | Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Partic Healthy Volunteer | N/A | 2023-01-05 |
| Recruiting | A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Phase 1 / Phase 2 | 2022-12-27 |
| Active Not Recruiting | A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (I Fibrodysplasia Ossificans Progressiva | Phase 3 | 2022-11-21 |
| Recruiting | An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-small Cell Lung Cancer | — | 2022-10-26 |
| Completed | A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants Healthy | Phase 1 | 2022-10-24 |
| Terminated | Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | 2022-10-06 |
| Completed | A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Intraocular Inflammation, Suspected Endophthalmitis | — | 2022-09-16 |
| Completed | A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Healthy | Phase 1 | 2022-09-15 |
| Recruiting | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Multiple Myeloma | Phase 1 | 2022-08-17 |
| Completed | Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conj Allergic Rhinitis, Conjunctivitis | Phase 2 | 2022-08-15 |
| Recruiting | A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Chronic Kidney Disease (CKD) | Phase 1 / Phase 2 | 2022-08-02 |
| Recruiting | A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Pati Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | 2022-08-01 |
| Active Not Recruiting | Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patien Melanoma | Phase 3 | 2022-07-14 |
| Completed | REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure Heart Failure | Phase 2 | 2022-06-30 |
| Completed | Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Foll Relapsed/Refractory Follicular Lymphoma | — | 2022-06-22 |
| Completed | Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Diffuse Large B-Cell Lymphoma | — | 2022-06-22 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Ad Healthy Volunteers | Phase 1 | 2022-04-13 |
| Completed | Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Re Healthy | Phase 1 | 2022-04-12 |
| Terminated | A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy, Metabolic Abnormalities | Phase 2 | 2022-02-28 |
| Completed | Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Derma Moderate-to-severe Atopic Dermatitis | — | 2022-01-27 |
| Terminated | A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | 2022-01-24 |
| Completed | COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Ant Healthy, Chronic Stable Illness | Phase 1 | 2022-01-07 |
| Terminated | COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 COVID-19 | Phase 1 | 2021-12-16 |
| Active Not Recruiting | A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well Th Generalized Myasthenia Gravis | Phase 3 | 2021-12-14 |
| Terminated | Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholi Non-alcoholic Steatohepatitis (NASH) | N/A | 2021-12-09 |
| Terminated | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | Phase 2 | 2021-11-30 |
| Recruiting | A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | 2021-11-30 |
| Terminated | Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transit Advanced NSCLC | Phase 1 | 2021-11-09 |
| Terminated | COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVI SARS-CoV-2 | Phase 1 / Phase 2 | 2021-11-08 |
| Completed | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Health Healthy Volunteers | Phase 1 | 2021-10-27 |
| Terminated | A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COV Immunocompromised | Phase 3 | 2021-10-25 |
| Withdrawn | Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossifican Fibrodyplasia Ossificans Progressiva (FOP), Heterotopic Ossification (HO) | Phase 3 | 2021-10-13 |
| Terminated | COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivima COVID-19 | Phase 2 | 2021-09-13 |
| Active Not Recruiting | Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinu Chronic Rhinosinusitis With Nasal Polyposis | — | 2021-08-12 |
| Completed | A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intra Healthy | Phase 1 | 2021-08-04 |
| Terminated | A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent an Allergic Rhinitis Due to Cat Allergy | Phase 3 | 2021-07-30 |
| Completed | Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | 2021-07-29 |
| Terminated | Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Rec Hypertriglyceridemia | Phase 2 | 2021-07-12 |
| Completed | Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Wh Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | 2021-07-08 |
| Completed | Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Ce Cervical Cancer | Phase 2 | 2021-06-28 |
| Completed | COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered Wi Healthy, Chronic Stable Illness | Phase 2 | 2021-04-29 |
| Completed | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Sev Moderate to Severe Atopic Hand and Foot Dermatitis | Phase 3 | 2021-04-14 |
| Terminated | CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma Melanoma, Advanced Melanoma, Metastatic Melanoma | Phase 2 | 2021-03-11 |
| Completed | Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis Conjunctivitis, Atopic Dermatitis | — | 2021-03-10 |
| Terminated | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma Melanoma, Advanced Melanoma, Metastatic Melanoma | Phase 2 / Phase 3 | 2021-02-24 |
| Active Not Recruiting | Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopath Retinopathy of Prematurity | — | 2021-02-05 |
| Terminated | CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Squamous Cell Carcinoma of Head and Neck | Phase 2 | 2021-01-21 |
| Completed | Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Al Allergic Rhinitis, Conjunctivitis | Phase 3 | 2021-01-14 |
| Terminated | REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Severe Aplastic Anemia (SAA) | Phase 1 | 2021-01-13 |
| Recruiting | A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Partic Advanced Solid Tumors | Phase 1 / Phase 2 | 2020-12-21 |
| Completed | COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult COVID-19 | Phase 2 | 2020-12-15 |
| Recruiting | A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplima Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | Phase 1 / Phase 2 | 2020-12-08 |
| Terminated | Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers Healthy Volunteer | Phase 1 | 2020-11-19 |
| Terminated | Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers Healthy Volunteer | Phase 1 | 2020-11-18 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in He Healthy | Phase 1 | 2020-11-16 |
| Withdrawn | Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma Hodgkin Lymphoma | Phase 2 | 2020-11-15 |
| Completed | T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Glu Celiac Disease | N/A | 2020-11-02 |
| Completed | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid Bullous Pemphigoid | Phase 2 / Phase 3 | 2020-10-28 |
| Terminated | Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies Squamous Cell Carcinoma of Head and Neck | Phase 1 | 2020-10-05 |
| Completed | Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERT Allergic Bronchopulmonary Aspergillosis | Phase 2 | 2020-09-15 |
| Completed | Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans Healthy | Phase 1 | 2020-09-01 |
| Completed | Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esoph Eosinophilic Esophagitis (EoE) | Phase 3 | 2020-09-01 |
| Completed | Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Health Healthy Volunteer | Phase 1 | 2020-08-03 |
| Completed | Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses Healthy, Chronic Stable Illness | Phase 1 | 2020-07-26 |
| Completed | A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma Asthma | Phase 4 | 2020-07-16 |
| Completed | COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention Healthy Participants | Phase 3 | 2020-07-13 |
| Completed | Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterol Homozygous Familial Hypercholesterolemia | Phase 3 | 2020-06-29 |
| Completed | Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | Phase 2 / Phase 3 | 2020-06-29 |
| Terminated | Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Amb COVID-19 | Phase 3 | 2020-06-16 |
| Completed | Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult P COVID-19 | Phase 1 / Phase 2 | 2020-06-10 |
| Completed | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 COVID-19 | Phase 2 / Phase 3 | 2020-03-18 |
| Completed | Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma Cutaneous Squamous Cell Carcinoma | Phase 2 | 2020-03-10 |
| Active Not Recruiting | Registry of Asthma Patients Initiating DUPIXENT® Asthma | — | 2020-03-02 |
| Completed | Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy ( CD55-deficient Protein-losing Enteropathy, CHAPLE | Phase 2 / Phase 3 | 2020-01-27 |
| Completed | Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy Generalized Lipodystrophy | Phase 2 | 2020-01-07 |
| Recruiting | A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non NSCLC | Phase 1 / Phase 2 | 2020-01-07 |
| Terminated | REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | 2019-12-03 |
| Active Not Recruiting | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin B-cell Non-Hodgkin Lymphoma (B-NHL) | Phase 2 | 2019-11-13 |
| Completed | Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneratio Neovascular (Wet) Age-Related Macular Degeneration | Phase 2 | 2019-11-04 |
| Completed | Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoag Retinopathy of Prematurity | Phase 3 | 2019-10-30 |
| Recruiting | An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD) Adverse Pregnancy Outcomes, Atopic Dermatitis | — | 2019-09-30 |
| Completed | First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | 2019-09-26 |
| Terminated | Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L Advanced PD-L1 Positive Malignancies | Phase 1 | 2019-09-04 |
| Recruiting | A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemipl Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 / Phase 2 | 2019-08-12 |
| Active Not Recruiting | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma | Phase 2 | 2019-07-23 |
| Completed | CemiplimAb Survivorship Epidemiology Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | — | 2019-06-27 |
| Active Not Recruiting | Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cut Cutaneous Squamous Cell Carcinoma | Phase 3 | 2019-06-04 |
| Completed | Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REG Healthy Volunteers, Birch Pollen Allergy | Phase 1 | 2019-06-03 |
| Terminated | A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee Osteoarthritis of the Knee, Pain | Phase 2 | 2019-05-21 |
| Completed | Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PN Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | 2019-05-16 |
| Completed | Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | Phase 1 | 2019-04-11 |
| Terminated | Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 2 | 2019-04-08 |
| Completed | Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy Peanut Allergy | Phase 2 | 2019-03-12 |
| Withdrawn | Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis Sporadic Inclusion Body Myositis | Phase 2 | 2019-02-19 |
| Completed | Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduc Cat Allergy, Mild Asthma | Phase 2 | 2019-02-12 |
| Completed | To Assess the Patients' Ability to Self-Administer Fasinumab Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 1 | 2019-01-23 |
| Recruiting | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma Multiple Myeloma | Phase 1 / Phase 2 | 2019-01-23 |
| Completed | Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe Chorioretinal Vascular Disease | Phase 4 | 2018-12-19 |
| Terminated | Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Sev Atopic Dermatitis | Phase 2 | 2018-11-13 |
| Terminated | Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Atopic Dermatitis | Phase 2 | 2018-11-12 |
| Completed | Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administra Atopic Dermatitis (AD), Asthma | — | 2018-10-24 |
| Completed | Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarth Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 2 | 2018-10-15 |
| Completed | Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR1 Peanut Allergy | Phase 2 | 2018-10-03 |
| Terminated | Long Term Safety Study of PRALUENT Heterozygous Familial Hypercholesterolemia, Non-familial Hypercholesterolemia | Phase 4 | 2018-09-28 |
| Terminated | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Saf Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor | Phase 1 / Phase 2 | 2018-09-24 |
| Completed | Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Eso Eosinophilic Esophagitis | Phase 3 | 2018-09-24 |
| Completed | Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers Healthy Volunteer | Phase 1 | 2018-08-23 |
| Terminated | REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Vers Non-small Cell Lung Cancer | Phase 3 | 2018-07-02 |
| Terminated | Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung C Carcinoma, Non-Small-Cell Lung | Phase 1 | 2018-06-27 |
| Completed | Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy Allergic Rhinitis | Phase 2 | 2018-06-07 |
| Completed | Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceri Severe Hypertriglyceridemia (sHTG) | Phase 2 | 2018-06-07 |
| Terminated | A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer Advanced Non-Small Cell Lung Carcinoma | Phase 2 | 2018-05-29 |
| Recruiting | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Rec Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer | Phase 1 / Phase 2 | 2018-05-21 |
| Completed | A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers Healthy Volunteers | Phase 1 | 2018-04-24 |
| Active Not Recruiting | Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) Dermatitis, Atopic | — | 2018-04-06 |
| Completed | Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer Non Small Cell Lung Cancer | Phase 1 | 2018-03-15 |
| Completed | Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterol Homozygous Familial Hypercholesterolemia | Phase 3 | 2018-03-13 |
| Completed | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Non-small Cell Lung Cancer | Phase 3 | 2018-03-06 |
| Completed | A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients Wit Fibrodysplasia Ossificans Progressiva | Phase 2 | 2018-02-26 |
| Completed | Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia Homozygous Familial Hypercholesterolemia | Phase 3 | 2018-01-18 |
| Terminated | Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study Hypercholesterolemia | — | 2017-12-19 |
| Completed | Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe A Dermatitis, Atopic | Phase 2 / Phase 3 | 2017-11-30 |
| Completed | Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in P Dermatitis, Atopic | Phase 3 | 2017-11-17 |
| Completed | Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia Hypercholesterolemia | Phase 2 | 2017-11-10 |
| Terminated | Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Os Chronic Low Back Pain, Osteoarthritis | Phase 3 | 2017-10-30 |
| Completed | Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflamma Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 3 | 2017-10-26 |
| Completed | Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) Homozygous Familial Hypercholesterolemia | Phase 3 | 2017-10-03 |
| Completed | Study of Cemiplimab in Adults With Cervical Cancer Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer | Phase 3 | 2017-09-05 |
| Completed | A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment o Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 3 | 2017-08-17 |
| Completed | An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Respon Recurrent Squamous Cell Carcinoma of Head, Recurrent Squamous Cell Carcinoma of Neck, Metastatic Squamous Cell Carcinoma of Head | Phase 1 | 2017-07-03 |
| Completed | PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Carcinoma, Basal Cell | Phase 2 | 2017-06-29 |
| Active Not Recruiting | Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japan Advanced Malignancies | Phase 1 | 2017-06-21 |
| Completed | Study of REGN3500 and Dupilumab in Patients With Asthma Asthma, Allergic | Phase 1 | 2017-06-15 |
| Completed | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lu Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma | Phase 3 | 2017-05-29 |
| Completed | Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers Healthy Volunteers | Phase 1 | 2017-05-16 |
| Completed | Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers Healthy Volunteers | Phase 1 | 2017-05-10 |
| Completed | Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Malignant Melanoma | Phase 1 | 2017-05-04 |
| Completed | An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Respon Melanoma | Phase 1 | 2017-04-10 |
| Completed | Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Derma Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin | Phase 3 | 2017-03-21 |
| Completed | Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis Atopic Disorders, Eczema, Atopic | Phase 1 | 2017-02-28 |
| Completed | Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Mod Asthma, Moderate Asthma | Phase 1 | 2017-02-03 |
| Completed | Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Heal Healthy Volunteers | Phase 1 | 2016-12-08 |
| Terminated | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumo Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | 2016-11-30 |
| Completed | Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers Malignancies | Phase 1 | 2016-11-07 |
| Completed | Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo Hypercholesterolemia | Phase 4 | 2016-11-02 |
| Completed | A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects Healthy Volunteers | Phase 1 | 2016-08-01 |
| Completed | A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477 Healthy Volunteers | Phase 1 | 2016-07-01 |
| Completed | Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers Healthy Volunteers | Phase 1 | 2016-05-27 |
| Completed | Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy Melanoma | Phase 1 | 2016-04-12 |
| Completed | Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma Advanced Cutaneous Squamous Cell Carcinoma | Phase 2 | 2016-04-07 |
| Completed | Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects Healthy Volunteers | Phase 1 | 2016-04-01 |
| Completed | Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macu Neovascular Age-Related Macular Degeneration | Phase 2 | 2016-03-31 |
| Completed | Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Nonproliferative Diabetic Retinopathy | Phase 3 | 2016-03-29 |
| Completed | Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for Diabetic Macular Edema | Phase 2 | 2016-03-02 |
| Completed | Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects Healthy | Phase 1 | 2016-03-01 |
| Completed | Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee Osteoarthritis of the Knee or Hip | Phase 3 | 2016-02-17 |
| Completed | A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Atopic Dermatitis | Phase 3 | 2016-01-31 |
| Completed | A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pa Low Back Pain | Phase 2 / Phase 3 | 2016-01-26 |
| Active Not Recruiting | A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignan Relapsed/Refractory Aggressive B-Cell Lymphoma | Phase 1 | 2016-01-11 |
| Completed | Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Se Atopic Dermatitis | Phase 1 | 2015-12-01 |
| Active Not Recruiting | Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age W Atopic Dermatitis | Phase 3 | 2015-10-15 |
| Withdrawn | Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study Advanced Malignancies | Phase 1 | 2015-08-01 |
| Completed | Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RS Respiratory Syncytial Virus Infections | Phase 3 | 2015-07-21 |
| Completed | Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects Healthy Volunteers | Phase 1 | 2015-07-01 |
| Completed | Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE) Eosinophilic Esophagitis | Phase 2 | 2015-05-12 |
| Terminated | Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AM Neovascular Age-Related Macular Degeneration | Phase 2 | 2015-05-05 |
| Completed | Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 2 / Phase 3 | 2015-05-01 |
| Completed | Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Und Heterozygous Familial Hypercholesterolemia | Phase 3 | 2015-03-31 |
| Completed | A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Y Atopic Dermatitis | Phase 2 | 2015-03-31 |
| Completed | A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatit Atopic Dermatitis | Phase 3 | 2015-03-25 |
| Completed | Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH) Homozygous Familial Hypercholesterolemia | Phase 2 | 2015-02-04 |
| Completed | Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies Advanced Cancer, Advanced Malignancies | Phase 1 | 2015-02-02 |
| Completed | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | 2015-01-09 |
| Completed | Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atop Dermatitis, Atopic | Phase 3 | 2014-11-30 |
| Completed | Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema | Phase 1 | 2014-11-01 |
| Completed | Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Al Allergy | Phase 1 | 2014-10-31 |
| Completed | Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis Dermatitis, Atopic | Phase 3 | 2014-10-01 |
| Terminated | Study of REGN1193 in Patients With Type 2 Diabetes Mellitus Diabetes Mellitus, Type 2 | Phase 1 | 2014-10-01 |
| Completed | Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Atopic Dermatitis | Phase 3 | 2014-09-01 |
| Completed | Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD) Atopic Dermatitis | Phase 2 | 2014-08-05 |
| Completed | Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers Healthy Volunteers | Phase 1 | 2014-05-01 |
| Completed | Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500 Metabolic Disorders | Phase 1 | 2014-04-01 |
| Completed | Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tociliz Rheumatoid Arthritis | Phase 1 | 2014-03-01 |
| Completed | Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD Neovascular Wet Age-related Macular Degeneration (AMD) | Phase 1 | 2014-02-01 |
| Completed | Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD) Atopic Dermatitis (AD) | Phase 2 | 2013-12-31 |
| Completed | Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia Sarcopenia | Phase 2 | 2013-11-01 |
| Completed | Open-label Study of Dupilumab in Patients With Atopic Dermatitis Atopic Dermatitis | Phase 3 | 2013-10-10 |
| Completed | Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR Hypercholesterolemia | Phase 3 | 2013-09-01 |
| Completed | Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Ad Allergy | Phase 1 | 2013-08-01 |
| Completed | An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193 Healthy Volunteers | Phase 1 | 2013-08-01 |
| Completed | Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786) Healthy Volunteers | Phase 1 | 2013-08-01 |
| Completed | Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers Healthy Volunteers | Phase 1 | 2013-06-01 |
| Completed | Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis Atopic Dermatitis | Phase 2 | 2013-05-01 |
| Completed | Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Heterozygous Familial Hypercholesterolemia | Phase 3 | 2012-12-01 |
| Completed | Study to Assess the Safety and Tolerability of Single Doses of REGN1500 Hypertriglyceridemia | Phase 1 | 2012-12-01 |
| Completed | Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) Hypercholesterolemia | Phase 3 | 2012-11-30 |
| Completed | Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degenerat Age - Related Macular Degeneration (AMD) | Phase 4 | 2012-11-01 |
| Completed | Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying T Hypercholesterolemia | Phase 3 | 2012-10-01 |
| Completed | Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Soli Solid Tumors | Phase 1 | 2012-10-01 |
| Completed | Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cance Cancer | Phase 1 | 2012-10-01 |
| Completed | Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786) Healthy Volunteers | Phase 1 | 2012-10-01 |
| Completed | Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or V Hypercholesterolemia | Phase 3 | 2012-09-30 |
| Completed | Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticoste Atopic Dermatitis | Phase 2 | 2012-07-01 |
| Terminated | Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Pruritus, Atopic Dermatitis | Phase 1 / Phase 2 | 2012-06-01 |
| Completed | Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis Atopic Dermatitis | Phase 2 | 2012-04-01 |
| Completed | Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) Branch Retinal Vein Occlusion | Phase 3 | 2012-04-01 |
| Completed | Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy Volunteers Healthy Volunteers | Phase 1 | 2012-03-01 |
| Completed | Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alir Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia | Phase 2 | 2012-02-28 |
| Completed | A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Hypercholesterolemia | Phase 2 | 2012-02-22 |
| Completed | A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786) Healthy Volunteers | Phase 1 | 2012-01-01 |
| Completed | Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously Healthy | Phase 1 | 2011-12-01 |
| Terminated | Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares Gout | Phase 3 | 2011-11-01 |
| Completed | Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol Intercritical Gout | Phase 4 | 2011-10-01 |
| Completed | Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis Atopic Dermatitis | Phase 1 | 2011-07-31 |
| Completed | Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema Diabetic Macular Edema | Phase 3 | 2011-05-01 |
| Completed | Study of Nesvacumab (REGN910/ SAR307746) Solid Tumors | Phase 1 | 2011-01-01 |
| Completed | Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia Hypercholesterolemia | Phase 2 | 2011-01-01 |
| Completed | Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Dermatitis | Phase 1 | 2010-12-01 |
| Completed | Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers Healthy | Phase 1 | 2010-11-01 |
| Completed | Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers Healthy | Phase 1 | 2010-08-01 |
| Completed | A Study of Tocilizumab in Patients With Rheumatoid Arthritis Rheumatoid Arthritis | — | 2010-08-01 |
| Completed | Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin Hypercholesterolemia | Phase 1 | 2010-06-01 |
| Completed | Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers Healthy Volunteers | Phase 1 | 2010-03-01 |
| Completed | Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("We Neovascular Age-related Macular Degeneration | Phase 3 | 2009-12-01 |
| Terminated | Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain Abdominal Pain Upper | Phase 2 | 2009-12-01 |
| Terminated | Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain Back Pain | Phase 2 | 2009-11-01 |
| Completed | Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers Healthy | Phase 1 | 2009-11-01 |
| Completed | A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatica | Phase 2 | 2009-11-01 |
| Completed | Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers Healthy | Phase 1 | 2009-10-01 |
| Completed | A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee Osteoarthritis of the Knee | Phase 1 / Phase 2 | 2009-08-01 |
| Completed | PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2) Gout | Phase 3 | 2009-07-01 |
| Completed | Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Ve Macular Edema Secondary to Central Retinal Vein Occlusion | Phase 3 | 2009-07-01 |
| Completed | A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Advanced Solid Malignancies | Phase 1 | 2009-06-01 |
| Completed | Study Utilizing Rilonacept in Gout Exacerbations Acute Gout Flare | Phase 3 | 2009-03-01 |
| Completed | Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE) Gout | Phase 3 | 2009-03-01 |
| Completed | PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1 Intercritical Gout | Phase 3 | 2009-02-01 |
| Completed | A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects Healthy | Phase 1 | 2009-02-01 |
| Completed | A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects Rheumatoid Arthritis | Phase 1 | 2008-12-01 |
| Completed | DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical I Diabetic Macular Edema | Phase 2 | 2008-12-01 |
| Terminated | A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Advanced Carcinoma, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2008-11-30 |
| Completed | A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis Rheumatoid Arthritis | Phase 1 | 2008-09-01 |
| Completed | Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis Rheumatoid Arthritis | Phase 1 | 2008-07-01 |
| Completed | Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares Gout | Phase 2 | 2007-11-01 |
| Completed | Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macul Macular Degeneration | Phase 3 | 2007-08-01 |
| Completed | Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD Macular Degeneration | Phase 2 | 2007-08-01 |
| Completed | Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD Neovascular Age Related Macular Degeneration | Phase 1 | 2006-10-01 |
| Completed | Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap Macular Degeneration | Phase 2 | 2006-04-01 |
| Completed | Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema Diabetic Macular Edema | Phase 1 | 2006-04-01 |
| Completed | Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS) | Phase 3 | 2005-12-01 |
| Completed | Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Sys Systemic Juvenile Idiopathic Arthritis | Phase 1 | 2005-11-01 |
| Completed | Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD Macular Degeneration | Phase 1 | 2005-06-01 |
| Completed | Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Cancer | Phase 1 | 2004-01-01 |
| Completed | Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Cancer | Phase 1 | 2004-01-01 |
| Completed | VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | 2002-04-01 |
| Completed | VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | 2001-11-01 |
| Approved For Marketing | Compassionate Use of Pozelimab CD55-deficient Protein-losing Enteropathy | — | — |
| Withdrawn | Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With N Chronic Kidney Disease, Anemia | Phase 2 | — |
| Withdrawn | A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of t Osteoarthritis | Phase 2 | — |
| Available | Compassionate Use of Ubamatamab Renal Medullary Carcinoma (RMC), Epithelioid Sarcoma | — | — |
| Approved For Marketing | Compassionate Use of Dupilumab Type 2 Inflammatory Disorders | — | — |
| No Longer Available | Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemogl Paroxysmal Nocturnal Hemoglobinuria | — | — |
| Available | A Compassionate Use (CU) Program of Odronextamab Relapsed or Refractory (R/R) Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Non-Hodgkin Lymphoma (NHL) | — | — |
| No Longer Available | Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Cutaneous Squamous Cell Carcinoma | — | — |
| Withdrawn | Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury Thermal Injury Pain | Phase 2 | — |
| Approved For Marketing | Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM) Multiple Myeloma | — | — |
| Temporarily Not Available | An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP) Fibrodysplasia Ossificans Progressiva (FOP) | — | — |
| Available | Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling Lipodystrophy, Generalized Lipodystrophy (GLD), Monogenic Obesity (MOB) | — | — |
| No Longer Available | Compassionate Use of Vidutolimod Refractory Melanoma | — | — |
| Approved For Marketing | Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid Bullous Pemphigoid | — | — |
| No Longer Available | Compassionate Use of REGN-COV2 for the Treatment of COVID-19 COVID-19 | — | — |
| Available | R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease Ebola Virus Disease | — | — |
| No Longer Available | Expanded Access Program of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Who Ha Food Allergy | — | — |
| Approved For Marketing | Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy CD55-Deficient Protein-Losing Enteropathy | — | — |
| Approved For Marketing | Compassionate Use of Evinacumab Pediatric Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (HTG), Dysbetalipoproteinemia (DBL) | — | — |
| Approved For Marketing | Expanded Access Use of Cemiplimab in Patients With Solid Tumors Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC), Cutaneous Squamous Cell Carcinoma (CSCC) | — | — |